Double maintains 1 strategies that include ATXS - Astria Therapeutics, Inc.
Current Value
$5.411 Year Return
Current Value
$5.411 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 63.84% | $4.99B | 0.35% |
GNOM | 59.71% | $44.85M | 0.5% |
IBB | 58.54% | $5.26B | 0.45% |
PBE | 56.99% | $228.06M | 0.58% |
IWC | 56.20% | $815.56M | 0.6% |
ARKG | 54.34% | $977.20M | 0.75% |
XPH | 53.56% | $155.05M | 0.35% |
IWO | 52.01% | $11.49B | 0.24% |
PINK | 51.75% | $132.75M | 0.5% |
IWM | 51.72% | $63.71B | 0.19% |
VTWO | 51.65% | $12.43B | 0.07% |
FBT | 51.02% | $1.04B | 0.54% |
BBH | 50.98% | $338.76M | 0.35% |
PTH | 50.69% | $105.01M | 0.6% |
KJUL | 50.67% | $120.33M | 0.79% |
SCHA | 50.56% | $17.18B | 0.04% |
GSSC | 50.23% | $557.11M | 0.2% |
IWN | 49.81% | $11.10B | 0.24% |
KJAN | 49.69% | $289.02M | 0.79% |
PRFZ | 49.60% | $2.37B | 0.34% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMTO | -21.92% | $5.10K | -99.92% | 0.00% |
CBOE | -15.47% | $23.34B | +31.58% | 1.12% |
VZ | -11.29% | $184.42B | +9.98% | 6.26% |
ED | -9.80% | $36.95B | +12.52% | 3.26% |
K | -9.80% | $28.31B | +38.89% | 2.82% |
ZCMD | -9.56% | $26.26M | -13.33% | 0.00% |
VSTA | -9.14% | $331.23M | +31.32% | 0.00% |
CME | -8.86% | $97.17B | +37.77% | 3.95% |
CL | -8.04% | $74.65B | -1.20% | 2.18% |
LITB | -6.62% | $21.77M | -74.81% | 0.00% |
NOC | -6.16% | $70.30B | +14.35% | 1.72% |
AEP | -5.86% | $54.46B | +15.89% | 3.59% |
AQB | -5.83% | $3.52M | -50.00% | 0.00% |
PPC | -5.80% | $10.70B | +45.42% | 0.00% |
MO | -5.58% | $100.92B | +30.61% | 6.82% |
KR | -4.63% | $43.03B | +28.80% | 1.97% |
AWK | -4.29% | $27.42B | +9.74% | 2.22% |
DUK | -4.14% | $90.43B | +14.83% | 3.58% |
T | -4.11% | $203.92B | +60.93% | 3.93% |
EXC | -4.03% | $43.29B | +23.40% | 3.60% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DNLI | 57.04% | $2.21B | -29.48% | 0.00% |
CRNX | 53.70% | $3.03B | -32.34% | 0.00% |
XENE | 52.87% | $2.48B | -15.90% | 0.00% |
COGT | 51.97% | $826.59M | -19.69% | 0.00% |
APGE | 50.78% | $2.53B | -4.22% | 0.00% |
GBIO | 49.25% | $26.21M | -88.15% | 0.00% |
CLDX | 48.96% | $1.36B | -43.29% | 0.00% |
IDYA | 48.81% | $1.92B | -44.38% | 0.00% |
BEAM | 47.68% | $1.80B | -31.35% | 0.00% |
BDTX | 47.57% | $134.76M | -62.02% | 0.00% |
DYN | 47.39% | $1.66B | -55.86% | 0.00% |
OCUL | 47.31% | $1.41B | +78.90% | 0.00% |
RGNX | 47.17% | $511.64M | -22.43% | 0.00% |
NRIX | 47.13% | $962.86M | -23.45% | 0.00% |
SNDX | 47.03% | $937.92M | -46.23% | 0.00% |
EYPT | 46.59% | $606.23M | -5.47% | 0.00% |
IMNM | 46.58% | $825.75M | -40.69% | 0.00% |
CELC | 46.24% | $472.95M | -16.73% | 0.00% |
ARCT | 46.20% | $337.38M | -59.95% | 0.00% |
ALEC | 46.13% | $162.99M | -65.32% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
OUNZ | -<0.01% | $1.69B | 0.25% |
AAAU | <0.01% | $1.49B | 0.18% |
SHV | 0.08% | $20.33B | 0.15% |
GLD | -0.10% | $100.24B | 0.4% |
FMF | -0.19% | $157.41M | 0.95% |
UTEN | -0.19% | $187.34M | 0.15% |
KRBN | 0.23% | $159.86M | 0.85% |
GSY | -0.28% | $2.76B | 0.22% |
BAR | -0.29% | $1.12B | 0.1749% |
SGOL | -0.32% | $5.17B | 0.17% |
IAU | -0.36% | $46.60B | 0.25% |
IBTP | 0.36% | $134.68M | 0.07% |
JPST | 0.42% | $31.49B | 0.18% |
IEF | -0.56% | $33.99B | 0.15% |
IBTO | -0.57% | $340.82M | 0.07% |
SHYM | -0.64% | $324.00M | 0.35% |
AGZ | -0.74% | $607.98M | 0.2% |
JSI | 0.76% | $833.00M | 0.49% |
CANE | -0.83% | $10.00M | 0.29% |
SMB | -0.91% | $272.79M | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -39.53% | $297.88M | 1.43% |
VIXY | -37.37% | $178.15M | 0.85% |
TAIL | -34.26% | $107.71M | 0.59% |
FXY | -18.71% | $855.96M | 0.4% |
IVOL | -18.66% | $357.32M | 1.02% |
IBMN | -14.46% | $447.69M | 0.18% |
XONE | -11.30% | $639.23M | 0.03% |
TPMN | -11.25% | $30.69M | 0.65% |
ULST | -10.87% | $667.10M | 0.2% |
UTWO | -10.50% | $374.45M | 0.15% |
SPTS | -10.15% | $5.78B | 0.03% |
STPZ | -8.91% | $451.37M | 0.2% |
XHLF | -8.74% | $1.64B | 0.03% |
VGSH | -8.64% | $22.42B | 0.03% |
CTA | -8.26% | $1.09B | 0.76% |
UNG | -8.21% | $362.09M | 1.06% |
TBLL | -7.80% | $2.23B | 0.08% |
IBTG | -7.71% | $1.94B | 0.07% |
GBIL | -7.68% | $6.05B | 0.12% |
UDN | -7.57% | $145.02M | 0.78% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STG | -0.01% | $32.24M | -0.16% | 0.00% |
FUBO | -0.07% | $1.15B | +169.60% | 0.00% |
UUU | 0.08% | $7.36M | +96.30% | 0.00% |
TEF | -0.26% | $29.51B | +15.71% | 5.96% |
HUSA | -0.29% | $8.56M | -56.67% | 0.00% |
CHD | -0.31% | $24.41B | -6.85% | 1.17% |
VHC | -0.38% | $37.77M | +135.71% | 0.00% |
ADC | -0.41% | $8.20B | +23.78% | 4.08% |
AMT | -0.42% | $100.35B | +10.60% | 3.04% |
UTZ | 0.46% | $1.16B | -26.39% | 1.79% |
KO | 0.50% | $310.21B | +14.62% | 2.74% |
MKTX | 0.54% | $8.44B | +11.89% | 1.32% |
HMY | -0.55% | $8.93B | +71.24% | 1.16% |
QNTM | -0.60% | $44.69M | -0.98% | 0.00% |
PRT | 0.73% | $47.57M | +4.83% | 10.98% |
BTU | 0.81% | $1.68B | -39.96% | 2.27% |
CYCN | 0.96% | $9.66M | +32.60% | 0.00% |
CNC | 1.17% | $27.50B | -18.37% | 0.00% |
RILY | 1.32% | $92.41M | -86.83% | 0.00% |
PULM | -1.62% | $30.39M | +340.19% | 0.00% |
Yahoo
BOSTON, June 13, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These results demonstrated robust overall reduction in the monthl
Finnhub
Astria Therapeutics, Inc. announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart , a monoclonal antibody...
Yahoo
BOSTON, June 06, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom.
Yahoo
BOSTON, June 03, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 shares of Astria’s common stock on June 2, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
Yahoo
BOSTON, May 28, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 4th at 1:25pm ET.
Yahoo
BOSTON, May 23, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025.